CN109674671A - The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid - Google Patents
The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid Download PDFInfo
- Publication number
- CN109674671A CN109674671A CN201910015399.3A CN201910015399A CN109674671A CN 109674671 A CN109674671 A CN 109674671A CN 201910015399 A CN201910015399 A CN 201910015399A CN 109674671 A CN109674671 A CN 109674671A
- Authority
- CN
- China
- Prior art keywords
- parts
- care
- care solution
- solution
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 239000007788 liquid Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000003750 conditioning effect Effects 0.000 title abstract 4
- 241001506047 Tremella Species 0.000 claims abstract description 44
- 150000004676 glycans Chemical class 0.000 claims abstract description 44
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 44
- 239000005017 polysaccharide Substances 0.000 claims abstract description 44
- 210000001215 vagina Anatomy 0.000 claims abstract description 42
- 241000186660 Lactobacillus Species 0.000 claims abstract description 37
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 37
- 238000000855 fermentation Methods 0.000 claims abstract description 33
- 230000004151 fermentation Effects 0.000 claims abstract description 33
- 239000006166 lysate Substances 0.000 claims abstract description 33
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 87
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 54
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 54
- 238000003756 stirring Methods 0.000 claims description 39
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 31
- -1 alkyl glycoside Chemical class 0.000 claims description 30
- 239000008367 deionised water Substances 0.000 claims description 29
- 229910021641 deionized water Inorganic materials 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000004310 lactic acid Substances 0.000 claims description 27
- 235000014655 lactic acid Nutrition 0.000 claims description 27
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical group CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 25
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 24
- 229930182470 glycoside Natural products 0.000 claims description 22
- 238000001816 cooling Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 18
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 15
- 229940051250 hexylene glycol Drugs 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 3
- 210000003905 vulva Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 238000004140 cleaning Methods 0.000 abstract description 17
- 241000894006 Bacteria Species 0.000 abstract description 12
- 230000007124 immune defense Effects 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000013312 nursing technique Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 106
- 230000000474 nursing effect Effects 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 8
- 238000005502 peroxidation Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000221198 Basidiomycota Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003670 easy-to-clean Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of vaginal care composition object and its application and the preparation methods of women secret conditioning liquid and women secret conditioning liquid comprising it, are related to women secret nursing technique field.The vaginal care composition object is mainly made of tremella polysaccharides and lactobacillus fermentation lysate, and the weight ratio of the tremella polysaccharides and lactobacillus fermentation lysate is 1~2:100.Wherein, tremella polysaccharides can be effectively improved body's immunity, inhibit cytolipin peroxidization；Lactobacillus fermentation lysate contains the newborn bacterium peptide of wide spectrum, has obvious containment to act on gram positive bacteria, and it can promote the increment of similar probiotics.The present invention, which compounds tremella polysaccharides with lactobacillus fermentation lysate, is made composition, the composition is while having cleaning bacteriostasis efficacy, also have flora at adjusting women secret unbalance, inhibit the peroxidization of cytolipin, and then improves the effect of vagina self-cleaning ability and immune defense function.
Description
Technical Field
The invention relates to the technical field of female private nursing, in particular to a vaginal nursing composition, application thereof, female private nursing liquid containing the vaginal nursing composition and a preparation method of the female private nursing liquid.
Background
The pudendal region of a woman is an important micro-ecological area of the woman, and is very complex and sensitive in structure, and the body has no other organs which have obvious different changes every month like the pudendal vagina. The stratum corneum of the pudendum is thin, but has hair protection, and besides general sweat glands, a plurality of special sebaceous glands are arranged under the pudendum hair to maintain the pH value and the lubricity of the pudendum skin. These glands are different from the common sweat glands in that they accumulate secretion in the glands and then secrete it out, and they change with the menstrual cycle, are easily blocked before the menstruation, are easily infected, and may even cause abscess and even gynecological diseases. It is known that the most abundant microorganism in vagina is lactobacillus, which accounts for 80-90% of total vaginal flora, and the quantity can reach 8000 ten thousand per ml, and its function is mainly to protect vagina from invasion of foreign bacteria, maintain weak acid environment in vagina, and secrete antibacterial substance. Is a healthy guard of the vagina, so the cleanness of the vagina and the quality of the self-cleaning function of the vagina are determined by the quantity of lactobacillus in vaginal secretion in medicine.
With the improvement of living standard, the consumption concept and the health concept of women are changing, more and more women begin to actively care for the lower part of the body, and the female care solution on the market is also of various varieties. At present, most of nursing solutions on the market are prepared in a chemical bacteriostasis mode, and the vaginal flora balance can be damaged after long-term use. Therefore, it is necessary and urgent to research and develop a female private care solution which has the effects of cleaning, bacteriostasis, mildness and no stimulation, and can balance the pH value of female private parts, improve the self-cleaning capability of vagina and improve the immune defense function.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a vaginal care composition, which has the effects of cleaning and inhibiting bacteria, and also has the effects of regulating the flora imbalance of female private parts, inhibiting the peroxidation of cell lipid and further improving the self-cleaning capability of the vagina and the immune defense function.
The second purpose of the invention is to provide the application of the vagina care composition, and the vagina care composition can be widely applied to the preparation process of female pudendum care products.
The third purpose of the invention is to provide a female private care solution, which comprises the vaginal care composition and an auxiliary agent acceptable in pharmacy or nursing science, and the female private care solution prepared from the components has the effects of cleaning, inhibiting bacteria, being mild and free of stimulation, and can balance the pH value of female private parts and improve the self-cleaning capability of vagina and the function of immune defense.
The fourth purpose of the invention is to provide a preparation method of the female private care solution, which has simple processing technology, does not need complex processing steps in the preparation process and is suitable for large-scale production and preparation.
The invention provides a vaginal nursing composition which mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is (1-2): 100.
the invention provides an application of a vagina nursing composition in preparing a female pudendum nursing product.
Further, the female pudendum care product is one of a care solution, a sanitary wet tissue, a sanitary gel or a care essential oil.
The female private care solution provided by the invention comprises the vaginal care composition and an auxiliary agent acceptable in pharmacy or nursing science.
Further, the auxiliary agent comprises a surfactant, a humectant, a pH regulator, a chelating agent, a preservative and a solvent.
Further, the surfactant is a mixture of amphoteric imidazoline and alkyl glycoside;
the humectant is propylene glycol;
the pH regulator is lactic acid;
the chelating agent is EDTA disodium;
the preservative is the mixture of p-hydroxyacetophenone and hexanediol;
the solvent is deionized water.
Further, the private care solution is mainly prepared from the following components in parts by weight: 1-10 parts of the vagina care composition, 10-20 parts of amphoteric imidazoline, 5-10 parts of alkyl glycoside, 1-5 parts of propylene glycol, 0.1-1.0 part of lactic acid, 0.1-1.0 part of EDTA disodium, 0.3-0.8 part of p-hydroxyacetophenone, 0.3-0.8 part of hexanediol and 51.2-82.19 parts of deionized water.
Furthermore, the private care solution is mainly prepared from the following components in parts by weight: 2-8 parts of the vagina care composition, 10-15 parts of amphoteric imidazoline, 5-8 parts of alkyl glycoside, 2-5 parts of propylene glycol, 0.2-0.8 part of lactic acid, 0.01-0.1 part of tremella polysaccharide, 0.2-0.8 part of EDTA disodium, 0.4-0.6 part of p-hydroxyacetophenone, 0.4-0.6 part of hexanediol and 55-80 parts of deionized water;
preferably, the private care solution is prepared from the following components in parts by weight: the vagina nursing composition comprises 5 parts of the vagina nursing composition, 10 parts of amphoteric imidazoline, 5 parts of alkyl glycoside, 3 parts of propylene glycol, 0.5 part of lactic acid, 0.03 part of tremella polysaccharide, 0.5 part of EDTA disodium, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 74.97 parts of deionized water.
The invention provides a preparation method of a female private nursing liquid, which comprises the following steps:
firstly, heating deionized water to 75-85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48-52 ℃, adding amphoteric imidazoline and alkyl glycoside into the homogeneous liquid A, and stirring and uniformly mixing to obtain homogeneous liquid B; then cooling to 38-42 ℃, adding the vagina nursing composition, propylene glycol and hexylene glycol, stirring and dissolving completely; and finally adding lactic acid to adjust the pH value of the solution to 4-4.5 to obtain the female private care solution.
Furthermore, the stirring speed in the preparation process is 2500-3000 rmp/min.
Compared with the prior art, the invention has the beneficial effects that:
the vagina nursing composition provided by the invention mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is (1-2): 100. the tremella polysaccharide is an acidic heteropolysaccharide, is obtained from tremella fruiting body, is a basidiomycete polysaccharide immunopotentiator, can effectively improve the immune function of an organism and promote the function of white blood cells, and also has the functions of inhibiting the peroxidation of cell lipid, promoting the growth of elastic cells and accelerating the regeneration of skin; meanwhile, the tremella polysaccharide can form a layer of uniform film with a certain thickness on the surface of the skin, so that the skin has good smooth feeling and moist feeling, does not shrink or feel tight, and has a protective effect on the skin. The lactobacillus fermentation lysate contains broad-spectrum lactobacillus peptide, has obvious inhibition effect on gram-positive bacteria, can promote the proliferation of similar probiotics, inhibit the overgrowth of harmful bacteria, deeply regulate flora imbalance, can clean and sterilize when being applied to a female care solution, and most importantly can balance the acid-base environment of vagina, recover the skin barrier of female private parts and protect the health of female private parts. According to the invention, the tremella polysaccharide and lactobacillus fermentation lysate are mixed according to the ratio of 1-2: 100, the composition has the effects of cleaning and inhibiting bacteria, and also has the effects of regulating the flora imbalance of female private parts, inhibiting the peroxidation of cell lipid, and further improving the self-cleaning capability of vagina and the immune defense function.
The vagina nursing composition provided by the invention can be widely applied to the preparation process of female pudendum nursing products.
The female private care solution provided by the invention comprises the vaginal care composition and pharmaceutically or physiologically acceptable auxiliaries, and has the effects of cleaning and inhibiting bacteria, and meanwhile, the female private care solution prepared from the components has the effects of regulating the flora imbalance of female private parts, inhibiting the peroxidation of cell lipids, and further improving the self-cleaning capability of vagina and the immune defense function.
The preparation method of the female private care solution comprises the steps of heating deionized water to 75-85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48-52 ℃, adding amphoteric imidazoline and alkyl glycoside into the homogeneous liquid A, and stirring and uniformly mixing to obtain homogeneous liquid B; then cooling to 38-42 ℃, adding the vagina nursing composition, propylene glycol and hexylene glycol, stirring and dissolving completely; and finally adding lactic acid to adjust the pH value of the solution to 4-4.5 to obtain the female private care solution. The preparation method has simple processing technology, does not need complex processing steps in the preparation process, and is suitable for large-scale production and preparation.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a microscopic image of the treated group and the physiological saline group after the culture in examples 1 and 2 provided in Experimental example 1 of the present invention.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments, and it should be understood that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
According to one aspect of the invention, the vaginal nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is (1-2): 100.
the vagina nursing composition provided by the invention mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is (1-2): 100. the tremella polysaccharide is an acidic heteropolysaccharide, is obtained from tremella fruiting body, is a basidiomycete polysaccharide immunopotentiator, can effectively improve the immune function of an organism and promote the function of white blood cells, and also has the functions of inhibiting the peroxidation of cell lipid, promoting the growth of elastic cells and accelerating the regeneration of skin; meanwhile, the tremella polysaccharide can form a layer of uniform film with a certain thickness on the surface of the skin, so that the skin has good smooth feeling and moist feeling, does not shrink or feel tight, and has a protective effect on the skin. The lactobacillus fermentation lysate contains broad-spectrum lactobacillus peptide, has obvious inhibition effect on gram-positive bacteria, can promote the proliferation of similar probiotics, inhibit the overgrowth of harmful bacteria, deeply regulate flora imbalance, can clean and sterilize when being applied to a female care solution, and most importantly can balance the acid-base environment of vagina, recover the skin barrier of female private parts and protect the health of female private parts. According to the invention, the tremella polysaccharide and lactobacillus fermentation lysate are mixed according to the ratio of 1-2: 100, the composition has the effects of cleaning and inhibiting bacteria, and also has the effects of regulating the flora imbalance of female private parts, inhibiting the peroxidation of cell lipid, and further improving the self-cleaning capability of vagina and the immune defense function.
According to one aspect of the invention, a vaginal care composition is used in the preparation of a feminine vulva care product.
The vagina nursing composition provided by the invention can be widely applied to the preparation process of female pudendum nursing products.
In a preferred embodiment of the present invention, the pudendal care product is one of a care solution, a sanitary wet tissue, a sanitary gel or a care essential oil.
According to one aspect of the invention, a female intimate care solution comprises the vaginal care composition described above and a pharmaceutically or physiologically acceptable auxiliary.
The female private care solution provided by the invention comprises the vaginal care composition and pharmaceutically or physiologically acceptable auxiliaries, and has the effects of cleaning and inhibiting bacteria, and meanwhile, the female private care solution prepared from the components has the effects of regulating the flora imbalance of female private parts, inhibiting the peroxidation of cell lipids, and further improving the self-cleaning capability of vagina and the immune defense function.
In a preferred embodiment of the present invention, the auxiliary agent includes a surfactant, a humectant, a PH adjuster, a chelating agent, a preservative, and a solvent.
In the above preferred embodiment, the surfactant is a mixture of amphoteric imidazoline and alkyl glycoside;
the humectant is propylene glycol;
the pH regulator is lactic acid;
the chelating agent is EDTA disodium;
the preservative is the mixture of p-hydroxyacetophenone and hexanediol;
the solvent is deionized water.
In a preferred embodiment of the invention, the private care solution is mainly prepared from the following components in parts by weight: 1-10 parts of the vagina care composition, 10-20 parts of amphoteric imidazoline, 5-10 parts of alkyl glycoside, 1-5 parts of propylene glycol, 0.1-1.0 part of lactic acid, 0.1-1.0 part of EDTA disodium, 0.3-0.8 part of p-hydroxyacetophenone, 0.3-0.8 part of hexanediol and 51.2-82.19 parts of deionized water.
In the preferred embodiment, the private care solution is mainly prepared from the following components in parts by weight: 2-8 parts of the vagina care composition, 10-15 parts of amphoteric imidazoline, 5-8 parts of alkyl glycoside, 2-5 parts of propylene glycol, 0.2-0.8 part of lactic acid, 0.01-0.1 part of tremella polysaccharide, 0.2-0.8 part of EDTA disodium, 0.4-0.6 part of p-hydroxyacetophenone, 0.4-0.6 part of hexanediol and 55-80 parts of deionized water;
preferably, the private care solution is prepared from the following components in parts by weight: the vagina nursing composition comprises 5 parts of the vagina nursing composition, 10 parts of amphoteric imidazoline, 5 parts of alkyl glycoside, 3 parts of propylene glycol, 0.5 part of lactic acid, 0.03 part of tremella polysaccharide, 0.5 part of EDTA disodium, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 74.97 parts of deionized water.
In the invention, the drug effect of the female private nursing liquid is further optimized by further adjusting and optimizing the dosage ratio of the raw materials of each component.
According to one aspect of the invention, the preparation method of the female private nursing liquid comprises the following steps:
firstly, heating deionized water to 75-85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48-52 ℃, adding amphoteric imidazoline and alkyl glycoside into the homogeneous liquid A, and stirring and uniformly mixing to obtain homogeneous liquid B; then cooling to 38-42 ℃, adding the vagina nursing composition, propylene glycol and hexylene glycol, stirring and dissolving completely; and finally adding lactic acid to adjust the pH value of the solution to 4-4.5 to obtain the female private care solution.
The preparation method of the female private care solution comprises the steps of heating deionized water to 75-85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48-52 ℃, adding amphoteric imidazoline and alkyl glycoside into the homogeneous liquid A, and stirring and uniformly mixing to obtain homogeneous liquid B; then cooling to 38-42 ℃, adding the vagina nursing composition, propylene glycol and hexylene glycol, stirring and dissolving completely; and finally adding lactic acid to adjust the pH value of the solution to 4-4.5 to obtain the female private care solution. The preparation method has simple processing technology, does not need complex processing steps in the preparation process, and is suitable for large-scale production and preparation.
In a preferred embodiment of the invention, the stirring speed in the preparation process is 2500-3000 rmp/min.
Preferably, the stirring speed in the preparation process is 2500-3000 rmp/min.
The technical solution of the present invention will be further described with reference to examples and comparative examples.
Example 1
The female privacy care solution is mainly prepared from the following components in parts by weight: 1 part of vaginal care composition, 10 parts of amphoteric imidazoline, 5 parts of alkyl glycoside, 1 part of propylene glycol, 0.1 part of lactic acid, 0.1 part of EDTA disodium, 0.3 part of p-hydroxyacetophenone, 0.3 part of hexanediol and 51.2 parts of deionized water;
the nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 1: 100, respectively;
the preparation method of the female private care solution comprises the following steps:
firstly, heating deionized water to 75 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48 ℃, adding amphoteric imidazoline and alkyl glucoside into the homogeneous liquid A, and uniformly stirring to obtain homogeneous liquid B; then cooling to 38 deg.C, adding the vaginal care composition, propylene glycol and hexylene glycol, stirring and dissolving completely; finally adding lactic acid to adjust the pH value of the solution to 4 to obtain female private care solution;
the stirring speed is 2500 rmp/min.
Example 2
The female privacy care solution is mainly prepared from the following components in parts by weight: 10 parts of vagina care composition, 20 parts of amphoteric imidazoline, 10 parts of alkyl glycoside, 5 parts of propylene glycol, 1.0 part of lactic acid, 1.0 part of EDTA disodium, 0.8 part of p-hydroxyacetophenone, 0.8 part of hexanediol and 82.19 parts of deionized water;
the nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 2: 100, respectively;
the preparation method of the female private care solution comprises the following steps:
firstly, heating deionized water to 85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 52 ℃, adding amphoteric imidazoline and alkyl glucoside into the homogeneous liquid A, and uniformly stirring to obtain homogeneous liquid B; then cooling to 42 deg.C, adding the vaginal care composition, propylene glycol and hexylene glycol, stirring and dissolving completely; finally adding lactic acid to adjust the pH value of the solution to 4.5 to obtain female private care solution;
the stirring speed is 3000 rmp/min.
Example 3
The female privacy care solution is mainly prepared from the following components in parts by weight: 3 parts of a vaginal care composition, 13 parts of amphoteric imidazoline, 6 parts of alkyl glycoside, 2 parts of propylene glycol, 0.3 part of lactic acid, 0.3 part of EDTA disodium, 0.4 part of p-hydroxyacetophenone, 0.4 part of hexanediol and 60 parts of deionized water;
the nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 1.2: 100, respectively;
the preparation method of the female private care solution comprises the following steps:
firstly, heating deionized water to 78 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 49 ℃, adding amphoteric imidazoline and alkyl glucoside into the homogeneous liquid A, and uniformly stirring to obtain homogeneous liquid B; then cooling to 39 deg.C, adding the vaginal care composition, propylene glycol and hexylene glycol, stirring and dissolving completely; finally adding lactic acid to adjust the pH value of the solution to 4.1 to obtain female private care solution;
the rotating speed for stirring is 2600 rmp/min.
Example 4
The female privacy care solution is mainly prepared from the following components in parts by weight: 8 parts of a vaginal care composition, 18 parts of amphoteric imidazoline, 9 parts of alkyl glycoside, 4 parts of propylene glycol, 0.8 part of lactic acid, 0.8 part of EDTA disodium, 0.6 part of p-hydroxyacetophenone, 0.6 part of hexanediol and 70 parts of deionized water;
the nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 1.8: 100, respectively;
the preparation method of the female private care solution comprises the following steps:
firstly, heating deionized water to 82 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 51 ℃, adding amphoteric imidazoline and alkyl glucoside into the homogeneous liquid A, and uniformly stirring to obtain homogeneous liquid B; then cooling to 41 ℃, adding the vagina nursing composition, propylene glycol and hexylene glycol, stirring and dissolving completely; finally adding lactic acid to adjust the pH value of the solution to 4.4 to obtain female private care solution;
the rotation speed for stirring is 2900 rmp/min.
Example 5
The female privacy care solution is mainly prepared from the following components in parts by weight: 5 parts of vagina care composition, 10 parts of amphoteric imidazoline, 5 parts of alkyl glycoside, 3 parts of propylene glycol, 0.5 part of lactic acid, 0.5 part of EDTA disodium, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 74.97 parts of deionized water;
the nursing composition mainly comprises tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 1.5: 100, respectively;
the preparation method of the female private care solution comprises the following steps:
firstly, heating deionized water to 80 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 50 ℃, adding amphoteric imidazoline and alkyl glucoside into the homogeneous liquid A, and uniformly stirring to obtain homogeneous liquid B; then cooling to 40 ℃, adding the vaginal care composition, propylene glycol and hexylene glycol, stirring and dissolving completely; finally adding lactic acid to adjust the pH value of the solution to 4.3 to obtain female private care solution;
the stirring speed is 2800 rmp/min.
Comparative example 1
This comparative example is the same as example 5 except that the amphoteric imidazoline content of the intimate care solution component was 5 parts.
Comparative example 2
This comparative example is the same as example 5 except that the amphoteric imidazoline content of the intimate care solution component was 15 parts.
Comparative example 3
This comparative example is the same as example 5 except that the privacy lotion component contained 0.5 parts propylene glycol.
Comparative example 4
This comparative example is the same as example 5 except that the intimate solution composition contains 2 parts disodium EDTA.
Comparative example 5
This comparative example is the same as example 5 except that the amount of deionized water in the intimate care solution component was 40 parts.
Experimental example 1
To show that the privacy care solution prepared by the invention has a stable formula system, the inventors tested the stability of the privacy care solutions prepared in examples 1 to 5 and comparative examples 1 to 5, and the results are shown in table 1:
table 1: stability detection results of private care solutions prepared in examples 1-5 and comparative examples 1-5 of the present invention
As can be seen from the table, the privacy care solution prepared in the embodiments 1-5 of the invention has moderate consistency and luster in appearance, has no phenomena of turbidity, precipitation and crystallization after standing for 80 days, and has moderate foam height. The solution system of the special care solution is obviously superior to the special care solution prepared in the comparative examples 1-5.
Compared with the comparative example 1, when the content of amphoteric imidazoline in the components of the private care solution is 5 parts, the content of the surfactant is lower, the care solution is thinner and slightly water-like, the care solution is slightly layered after standing for 80 days, and meanwhile, the foam is less and the use is inconvenient;
comparative example 2 when the content of amphoteric imidazoline in the composition of the intimate care solution was 15 parts, the surfactant content was high, and the care solution was turbid, lackluster, too much foam and not easy to clean.
Comparative example 3 when the propylene glycol content of the intimate care solution component was 0.5 parts, the humectant content was lower and the lather was also lower; (ii) a
Comparative example 4 when the content of disodium EDTA in the private care solution component was 2 parts, the chelating agent content was high, and the care solution appeared to be slightly crystallized after standing for 80 days;
comparative example 5 when the content of deionized water in the components of the intimate care solution was 40 parts, the care solution was viscous and not easy to pour out, slight precipitation occurred after standing for 80 days, and excessive foam was not easy to clean.
Experimental example 2
Bacteriostatic experiments of the nursing liquid on pathogenic bacteria: candida albicans is selected to test the inhibition effect of the private care solution prepared in the embodiment 1-5 on pathogenic bacteria.
The inoculation mode adopts a test tube to inoculate candida albicans. In the experimental example, a blank group, a positive control group, a normal saline group and a treatment group were set, and the products prepared in examples 1 to 5 were used in the treatment group.
Wherein,
blank control group: only 15ml of Sabouraud's medium.
Positive control group: taking the number of strains as 1 × 1030.5ml of the strain of Nelumbo Nucifera is inoculated into 15ml of Sabouraud's medium and cultured at 37 ℃ for 48 hours at 220 r/min.
Physiological saline group: taking the number of strains as 1 × 1030.5ml of the strain of Nelumbo Nucifera is inoculated into 15ml of Sabouraud's medium, and then 0.5ml of physiological saline is added to the strain to culture the strain at 37 ℃ and 220r/min for 48 hours.
Treatment group: taking the number of strains as 1 × 1030.5ml of the white streptococci is inoculated in 15ml of the Sabouraud's medium, then 0.5ml of the product of the invention is added, and the mixture is cultured for 48 hours at 37 ℃ under the condition of 220 r/min.
The experimental results are as follows: compared with the positive control group without the private care solution, the culture solution transparency of the treatment group is clear and transparent, and the positive control group is white turbid solution. The clarity of the treated group was consistent with that of the blank control group and the saline group, indicating that the growth of Streptococcum albus was completely inhibited after the addition of the privacy lotion.
Meanwhile, the treated groups and the normal saline group after the culture in examples 1 and 2 were subjected to microscopic observation experiments, and morphological changes of Candida albicans were observed under a 400-fold microscope.
As shown in figure 1, the bacteriostatic effect of the care solution added with the vaginal care composition in the examples 1 and 2 is very obvious, and the bacteriostatic effect of the care solution added with more parts by weight of the vaginal care composition in the example 2 is better than that of the care solution added with less parts by weight of the vaginal care composition in the example 1.
Experimental example 3
Lactobacillus acidophilus is selected to test the influence of the private care solution prepared in examples 1-5 on probiotics. The inoculation mode adopts a test tube to inoculate lactobacillus acidophilus. In the experimental example, a blank group, a positive control group, a normal saline group and a treatment group were set, and the products prepared in examples 1 to 5 were used in the treatment group.
Wherein,
blank control group: only 15ml of MRS medium.
Positive controlGroup (2): taking the number of strains as 1 × 1050.5ml of the Lactobacillus acidophilus is inoculated in 15ml of MRS medium and cultured for 24 hours at 37 ℃ and 220 r/min.
Physiological saline group: taking the number of strains as 1 × 1050.5ml of Lactobacillus acidophilus is inoculated in 15ml of MRS medium, and then 0.5ml of normal saline is added to culture for 24 hours at 37 ℃ and 220 r/min.
Treatment group: taking the number of strains as 1 × 105Inoculating 0.5ml of Lactobacillus acidophilus into 15ml of Sabouraud's medium, adding 0.5ml of the product of the invention, and culturing at 37 ℃ and 220r/min for 48 h.
The experimental results are as follows: compared with the positive control group without the private care solution, the culture solution turbidity of the treatment group added with the private care solution is consistent with that of the positive control group, and the culture solution turbidity is light yellow turbid solution. The blank control group and the physiological saline group are clear and transparent liquids. The results show that the growth of the probiotic bacteria is not inhibited by the addition of the intimate care solution, in other words, the intimate care solution protects the growth of the probiotic bacteria.
Comparative example 6
The weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate in the vagina-removing and nursing composition is 3: 100, the same as example 5.
Comparative example 7
The weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate in the vagina-removing and nursing composition is 0.5: 100, the same as example 5.
Comparative example 8
The comparison example is the same as the vagina nursing composition except that the tremella polysaccharide in the vagina nursing composition is replaced by the lentinan
Example 5.
Experimental example 4
In order to show that the privacy care solution of the invention has the effect of inhibiting the peroxidation of cell lipids, experiments of DPPH free radical antioxidant reaction were carried out by using the care solutions prepared in examples 1-5 and comparative examples 6-8.
DPPH is an early synthetic organic radical commonly used to evaluate the hydrogen donating ability of antioxidants, is very stable in organic solvents, is purple in color, and has a characteristic absorption peak where upon encountering a radical scavenger, the lone pair of electrons of DPPH is paired to cause discoloration, i.e., the absorbance at the maximum absorption wavelength becomes small. Therefore, the effect of the sample on DPPH radical scavenging can be evaluated by measuring the change in absorbance.
The specific experimental steps of the DPPH free radical scavenging experiment are as follows:
(1) mixing the same volume (3mL) of the solution to be detected with 2X 10mol/L of DPPH solution (A1 tube);
(2) taking absolute ethyl alcohol (solvent of a substance to be detected) with the same volume and uniformly mixing the absolute ethyl alcohol with 2 multiplied by 10 < -4 > mol/L DPPH solution (A2 tube);
(3) taking absolute ethyl alcohol with the same volume and uniformly mixing the absolute ethyl alcohol with a solution to be detected (A3 tube);
(4) after 30min of reaction, the absorbance values of A1, A2 and A3 tubes were measured at 517 nm.
The clearance calculation formula is: clearance (%) [ (A2+ A3) -A1]/A2
The greater the clearance rate, the greater the antioxidant capacity.
The results are shown in the following table:
as can be seen from the table, the DPPH free radical clearance rate of the care solution prepared in the embodiments 1 to 5 can reach more than 68%, and the care solution has good oxidation resistance.
And comparative example 7 the weight ratio of tremella polysaccharide to lactobacillus fermentation lysate was 0.5: 100, and comparative example 8, the DPPH free radical clearance rate is poor, and the corresponding antioxidant property is not available; and the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate in the comparative example 6 is 3: 100, the clearance rate of the care solution to DPPH free radicals is almost the same, and in consideration of economy, when the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is 1-2: 100 has good technical effect.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. The vaginal care composition is characterized by mainly comprising tremella polysaccharide and lactobacillus fermentation lysate, wherein the weight ratio of the tremella polysaccharide to the lactobacillus fermentation lysate is (1-2): 100.
2. use of the vaginal care composition of claim 1 in the preparation of a feminine vulva care product.
3. The use of claim 2, wherein the feminine hygiene product is one of a care solution, a sanitary wet wipe, a sanitary gel, or a care essential oil.
4. A female intimate care solution comprising the vaginal care composition of claim 1 and a pharmaceutically or physiologically acceptable auxiliary.
5. The female intimate care solution of claim 4 wherein the auxiliary agent comprises a surfactant, a humectant, a pH adjuster, a chelating agent, a preservative, and a solvent.
6. The female intimate care solution of claim 5 wherein the surfactant is a mixture of amphoteric imidazoline and alkyl glycoside;
the humectant is propylene glycol;
the pH regulator is lactic acid;
the chelating agent is EDTA disodium;
the preservative is the mixture of p-hydroxyacetophenone and hexanediol;
the solvent is deionized water.
7. The female privacy care solution of claim 4, wherein the privacy care solution is prepared from the following components in parts by weight: the vaginal care composition of claim 1 to 10 parts, amphoteric imidazoline 10 to 20 parts, alkyl glycoside 5 to 10 parts, propylene glycol 1 to 5 parts, lactic acid 0.1 to 1.0 part, disodium EDTA 0.1 to 1.0 part, p-hydroxyacetophenone 0.3 to 0.8 part, hexylene glycol 0.3 to 0.8 part, and deionized water 51.2 to 82.19 parts.
8. The female privacy care solution of claim 7, wherein the privacy care solution is prepared from the following components in parts by weight: 2-8 parts of the vagina care composition, 10-15 parts of amphoteric imidazoline, 5-8 parts of alkyl glycoside, 2-5 parts of propylene glycol, 0.2-0.8 part of lactic acid, 0.01-0.1 part of tremella polysaccharide, 0.2-0.8 part of EDTA disodium, 0.4-0.6 part of p-hydroxyacetophenone, 0.4-0.6 part of hexanediol and 55-80 parts of deionized water;
preferably, the private care solution is prepared from the following components in parts by weight: the vaginal care composition of claim 1, comprising 5 parts of amphoteric imidazoline, 5 parts of alkyl glycoside, 3 parts of propylene glycol, 0.5 part of lactic acid, 0.03 part of tremella polysaccharide, 0.5 part of disodium EDTA, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexylene glycol, and 74.97 parts of deionized water.
9. A method for preparing a female privacy care solution according to any one of claims 4 to 8, wherein the method comprises the following steps:
firstly, heating deionized water to 75-85 ℃, adding p-hydroxyacetophenone and EDTA disodium, mixing and stirring to obtain a homogeneous liquid A; then cooling to 48-52 ℃, adding amphoteric imidazoline and alkyl glycoside into the homogeneous liquid A, and stirring and uniformly mixing to obtain homogeneous liquid B; then cooling to 38-42 ℃, adding the vaginal care composition as claimed in claim 1, propylene glycol and hexylene glycol, and stirring to dissolve completely; and finally adding lactic acid to adjust the pH value of the solution to 4-4.5 to obtain the female private care solution.
10. The preparation method of the female privacy care solution, as claimed in claim 9, wherein the stirring speed in the preparation process is 2500-3000 rmp/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910015399.3A CN109674671A (en) | 2019-01-07 | 2019-01-07 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910015399.3A CN109674671A (en) | 2019-01-07 | 2019-01-07 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109674671A true CN109674671A (en) | 2019-04-26 |
Family
ID=66192005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910015399.3A Pending CN109674671A (en) | 2019-01-07 | 2019-01-07 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109674671A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051618A (en) * | 2019-05-16 | 2019-07-26 | 上海复沣生物科技有限公司 | A kind of microecological balance care composition and product |
| CN110585114A (en) * | 2019-09-30 | 2019-12-20 | 华熙生物科技股份有限公司 | Bactericidal composition for regulating skin microbial flora and application thereof |
| CN110664728A (en) * | 2019-10-30 | 2020-01-10 | 江苏梦达日用品有限公司 | Skin bacteriostatic agent |
| CN111803436A (en) * | 2020-04-29 | 2020-10-23 | 浙江伊瑟奇医药科技有限公司 | Private part self-cleaning repair essence based on bioactive polysaccharide and active polypeptide and preparation method thereof |
| CN112220737A (en) * | 2020-11-24 | 2021-01-15 | 广州市拓瑞科技有限公司 | Female private nursing gel and preparation method thereof |
| CN117180492A (en) * | 2023-09-26 | 2023-12-08 | 吉林省七维生物科技有限公司 | Gel dressing composition containing silk fibroin, preparation method and application |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965787A (en) * | 2005-11-17 | 2007-05-23 | 关长宽 | Vagina lubrication liquid used in climacteric period |
| CN103157095A (en) * | 2013-02-22 | 2013-06-19 | 云南康洲生物科技有限公司 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
| CN104800894A (en) * | 2015-04-30 | 2015-07-29 | 重庆市海洁消毒卫生用品有限责任公司 | Formula and preparation method of human lubricant |
| CN105288218A (en) * | 2015-11-23 | 2016-02-03 | 西安木本贞生物科技有限公司 | Probiotics composite |
| CN106177901A (en) * | 2016-08-31 | 2016-12-07 | 哈尔滨欧替药业有限公司 | A kind of pudendum facial film |
| CN106692946A (en) * | 2015-07-23 | 2017-05-24 | 北京市天宜茗妆生物科技有限责任公司 | Composition for relieving vaginal relaxation, and preparation and preparing method thereof |
| CN107753310A (en) * | 2017-09-04 | 2018-03-06 | 广州市拓瑞化工科技有限公司 | A kind of gentle three-in-one washing lotion of the non-stimulated antibacterial cleaning-nursing of women privates and preparation method thereof of new type of safe |
| CN107998035A (en) * | 2017-12-30 | 2018-05-08 | 广州市中通生化制品有限公司 | A kind of Essence of antiallergic maintenance and preparation method thereof |
| CN108042578A (en) * | 2018-02-18 | 2018-05-18 | 王甲林 | A kind of health care vaginal jellies containing compound probiotic ingredient |
| CN108968025A (en) * | 2018-06-13 | 2018-12-11 | 江苏新申奥生物科技有限公司 | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid |
-
2019
- 2019-01-07 CN CN201910015399.3A patent/CN109674671A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965787A (en) * | 2005-11-17 | 2007-05-23 | 关长宽 | Vagina lubrication liquid used in climacteric period |
| CN103157095A (en) * | 2013-02-22 | 2013-06-19 | 云南康洲生物科技有限公司 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
| CN104800894A (en) * | 2015-04-30 | 2015-07-29 | 重庆市海洁消毒卫生用品有限责任公司 | Formula and preparation method of human lubricant |
| CN106692946A (en) * | 2015-07-23 | 2017-05-24 | 北京市天宜茗妆生物科技有限责任公司 | Composition for relieving vaginal relaxation, and preparation and preparing method thereof |
| CN105288218A (en) * | 2015-11-23 | 2016-02-03 | 西安木本贞生物科技有限公司 | Probiotics composite |
| CN106177901A (en) * | 2016-08-31 | 2016-12-07 | 哈尔滨欧替药业有限公司 | A kind of pudendum facial film |
| CN107753310A (en) * | 2017-09-04 | 2018-03-06 | 广州市拓瑞化工科技有限公司 | A kind of gentle three-in-one washing lotion of the non-stimulated antibacterial cleaning-nursing of women privates and preparation method thereof of new type of safe |
| CN107998035A (en) * | 2017-12-30 | 2018-05-08 | 广州市中通生化制品有限公司 | A kind of Essence of antiallergic maintenance and preparation method thereof |
| CN108042578A (en) * | 2018-02-18 | 2018-05-18 | 王甲林 | A kind of health care vaginal jellies containing compound probiotic ingredient |
| CN108968025A (en) * | 2018-06-13 | 2018-12-11 | 江苏新申奥生物科技有限公司 | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051618A (en) * | 2019-05-16 | 2019-07-26 | 上海复沣生物科技有限公司 | A kind of microecological balance care composition and product |
| CN110585114A (en) * | 2019-09-30 | 2019-12-20 | 华熙生物科技股份有限公司 | Bactericidal composition for regulating skin microbial flora and application thereof |
| CN110585114B (en) * | 2019-09-30 | 2022-06-10 | 华熙生物科技股份有限公司 | Bactericidal composition for regulating skin microbial flora and application thereof |
| CN110664728A (en) * | 2019-10-30 | 2020-01-10 | 江苏梦达日用品有限公司 | Skin bacteriostatic agent |
| CN111803436A (en) * | 2020-04-29 | 2020-10-23 | 浙江伊瑟奇医药科技有限公司 | Private part self-cleaning repair essence based on bioactive polysaccharide and active polypeptide and preparation method thereof |
| CN112220737A (en) * | 2020-11-24 | 2021-01-15 | 广州市拓瑞科技有限公司 | Female private nursing gel and preparation method thereof |
| CN117180492A (en) * | 2023-09-26 | 2023-12-08 | 吉林省七维生物科技有限公司 | Gel dressing composition containing silk fibroin, preparation method and application |
| CN117180492B (en) * | 2023-09-26 | 2024-04-26 | 吉林省七维生物科技有限公司 | Gel dressing composition containing silk fibroin, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674671A (en) | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid | |
| JP2019118346A (en) | Probiotics composition, skin care essence and mask as well as method for producing the same | |
| CN110638740A (en) | Composition capable of regulating skin micro-ecology and application thereof | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| CN106420493A (en) | Hyaluronic acid toothpaste with effects of diminishing inflammation and inhibiting bacteria and preparation method of hyaluronic acid toothpaste | |
| KR102125316B1 (en) | cosmetic composition for anti-irritation and skin soothing using Lactobacillus pentosus J2K-185strain | |
| CN103405592A (en) | Bacteriostatic water-soluble personal lubricant and preparation method thereof, and condom | |
| KR102115668B1 (en) | Cosmetic composition having anti-acne activity comprising probiotics fermentation product | |
| CN111632019A (en) | Silk fibroin skin beautifying gel and preparation method thereof | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN111481498A (en) | Antibacterial gel for regulating microecological balance of female vagina and preparation method thereof | |
| CN114569536A (en) | A lotion for improving microecology and physiological state of aged skin | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN109078069B (en) | Vaginal mucosa antibacterial gel and preparation method thereof | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| CN116531547B (en) | Cedar plant extract anti-allergy repair essence disposable sanitary product nursing base material, preparation method and application | |
| CN108652999B (en) | A kind of children's toothpaste and preparation method thereof | |
| CN111904909A (en) | Dandruff-removing scalp essence containing rose fermentation liquor and preparation method thereof | |
| CN115252460B (en) | Acne-removing composition containing antibacterial peptide, and preparation method and application thereof | |
| CN110613648A (en) | Skin care composition capable of improving skin barrier and application thereof | |
| CN110974775A (en) | Allergy-relieving composition containing nostoc sphaeroides and preparation method and application thereof | |
| CN108743502A (en) | A kind of bamboo vinegar toothpaste and preparation method thereof | |
| CN109692142B (en) | Poria cocos facial cleanser and preparation method thereof | |
| CN109745241B (en) | Poria cocos mask liquid and preparation method thereof | |
| CN117298198B (en) | Microalgae extract and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190426 |